Amino Nitrogen And A Ring Bonded Directly To The Same Ring And Any Other Amino Nitrogen In The Compound Is Bonded Directly To One Of The Rings Patents (Class 514/647)
-
Publication number: 20110059905Abstract: Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.Type: ApplicationFiled: March 31, 2009Publication date: March 10, 2011Inventors: Theresa A. Zesiewicz, Kelly L. Sullivan
-
Publication number: 20110038807Abstract: The present invention is directed to a method for treating bipolar disorder, childhood-onset bipolar disorder, and associated symptoms. The method includes administering to a subject in need of such treatment a dose of ketamine sufficient to alleviate symptoms associated with bipolar disorder and childhood-onset bipolar disorder.Type: ApplicationFiled: August 14, 2009Publication date: February 17, 2011Inventor: Demitri Papolos
-
Publication number: 20110021502Abstract: The invention discloses the use of cholinesterase inhibitors in treating vascular depression.Type: ApplicationFiled: August 25, 2010Publication date: January 27, 2011Inventor: Roger Michael LANE
-
Publication number: 20100324147Abstract: Described herein are arylcyclopropylamine compounds that may inhibit enzymes comprising an amine oxidase domain, such as LSD1, MAO A and/or MAO B.Type: ApplicationFiled: June 2, 2010Publication date: December 23, 2010Inventors: Dewey G. McCafferty, Julie Pollock
-
Patent number: 7855233Abstract: The subject invention provides rasagiline citrate, its compositions and processes for the manufacture thereof.Type: GrantFiled: January 18, 2010Date of Patent: December 21, 2010Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Anton Frenkel, Muhammad Safadi, Tamas Koltai
-
Patent number: 7846469Abstract: Methods and pharmaceutical compositions are disclosed for reversibly inhibiting sperm receptor activity in animals. Nicarbazin, its derivatives and modifications which retain pharmacological activity are shown to inhibit activity of zona pellucida proteins and concomitant synthesis and/or assembly of the sperm receptor on the oocyte surface necessary for fertilization. Nicarbazin is easily administered, for example by simple addition to feed of an animal and is and non-toxic to the animals, providing a safe and efficient means for controlling populations of mammals and avian species.Type: GrantFiled: August 3, 2007Date of Patent: December 7, 2010Assignee: The Penn State Research FoundationInventors: Guy F. Barbato, Alexander MacDonald
-
Publication number: 20100305095Abstract: The present invention relates to, inter alia, the use of a compound capable of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) in an animal in the manufacture of a medicament for use in the treatment and/or prevention of depression. The invention also provides for the use of a compound capable of inhibiting HPPD in an animal in the manufacture of a medicament for use in the treatment of the withdrawal symptoms associated with an addictive drug which causes dopamine dependant associative learning disorders in said animal. In a particular embodiment said HPPD inhibitor is selected from the group consisting of the compound depicted as compound 1; 2; and 3.22.Type: ApplicationFiled: August 18, 2006Publication date: December 2, 2010Inventors: Kim Zachary Travis, John Posner
-
Publication number: 20100305212Abstract: The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders mediated by GPCRs.Type: ApplicationFiled: June 13, 2008Publication date: December 2, 2010Applicant: University of Florida Research Foundation, Inc.Inventor: Raymond G. Booth
-
Publication number: 20100303903Abstract: The invention relates to methods of enhancing selective serotonin reuptake inhibitor effects in mammals. In particular, the invention provides methods for treating selective serotonin reuptake inhibitor dependent conditions such as depression. More specifically, the present invention relates to a method of increasing the antidepressant activity of a selective serotonin reuptake inhibitor (“SSRI”) by administering L-lysine-d-amphetamine in combination with an SSRI and to formulates containing the same. In a preferred aspect, the combination is administered in connection with a method of treating depression. One preferred SSRI is escitalopram. The preferred amphetamine prodrug is L-lysine-d-amphetamine.Type: ApplicationFiled: May 26, 2010Publication date: December 2, 2010Applicant: SHIRE LLCInventor: David HACKETT
-
Publication number: 20100297077Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.Type: ApplicationFiled: October 3, 2008Publication date: November 25, 2010Applicant: BIONOMICS LIMITEDInventors: Bernard Luke Flynn, Jonathan Bayldon Baell, Jason Hugh Chaplin, Girmit Singh Gill, Damian Wojciech Grobelny, Andrew John Harvey, Jorgen Alvar Mould, Dharam Paul
-
Publication number: 20100292292Abstract: Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy, or other neurodegenerative diseases (e.g., amyotrophic lateral sclerosis, Huntington's disease, and Alzheimer's disease) are provided. The treatment including administering to a subject an indatraline derivative that inhibits the aggregation of ?-synuclein.Type: ApplicationFiled: September 12, 2008Publication date: November 18, 2010Applicant: LINK MEDICINE CORPORATIONInventors: Peter T. Lansbury, JR., Craig J. Justman
-
Publication number: 20100292340Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.Type: ApplicationFiled: July 30, 2010Publication date: November 18, 2010Applicant: SEPRACOR INC.Inventors: Thomas P. JERUSSI, Qun Kevin FANG, Mark G. CURRIE
-
Publication number: 20100279990Abstract: The present invention provides a compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR6, OC(O)R6, C(O)R6 C(S)R6, CO2R6, C(O)SR6, C(O)NR6R7, C(S)NR6R7, NR6R7, NR6C(O)R7, NR6C(S)R7, NR6C(O)NR7R8, NR6C(S)NR7R8, NR6SO2R7, NR6SO2NR7R8, SR6, SC(O)R6, SC(O)NR6R7, S(O)R6, SO2R6, SO2NR6R7, or NR6SO2R7R8. Also provided is a pharmaceutical composition that includes one or more compounds of the present invention, and methods of therapeutically using and processes for producing such compounds and compositions.Type: ApplicationFiled: June 8, 2007Publication date: November 4, 2010Applicants: RAMOT AT TEL-AVIV UNIVERSITY LTD., PERRIGO ISRAEL PHARMACEUTICALS LTD.Inventors: Irit Gil-Ad, Moshe Portnoy, Avraham Weizman, Liat Lomnitski
-
Publication number: 20100272808Abstract: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.Type: ApplicationFiled: April 29, 2010Publication date: October 28, 2010Inventors: Bret Berner, Jenny Louie-Helm, Gloria Gusler, John N. Shell
-
Patent number: 7820688Abstract: Many chemical and pharmaceutical compositions are known to produce antinociceptive effects that are helpful in relieving pain and inflammation. Both opioids and local anesthetics serve an important function in providing peripheral pain relief. Topical administration of pain-relieving drugs to the periphery offers important advantages over systemic or local, non-topical administration. The present invention provides topical pharmaceutical compositions, formulated with at least one local anesthetic and at least one opioid analgesic in a topical excipient. The present invention also provides methods for relieving pain in a subject through topical administration of the pharmaceutical composition in an amount and a duration sufficient to synergistically potentiate an antinociceptive response. Synergistic potentiation of analgesia through topical administration of a local anesthetic/opioid pharmaceutical composition provides a new and improved approach to peripheral pain management.Type: GrantFiled: April 13, 2004Date of Patent: October 26, 2010Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Gavril Pasternak, Yuri Kolesnikov
-
Publication number: 20100256116Abstract: A method of screening a subject for a serotonergic neurotransmission dysregulation disorder comprises detecting the presence or absence of an Tph2 mutation in the subject; and then determining that the subject is at increased risk of a serotonergic neurotransmission dysregulation disorder due to the presence or absence of the Tph2 mutation.Type: ApplicationFiled: July 28, 2009Publication date: October 7, 2010Inventors: Marc G. Caron, Xiaodong Zhang, Martin Beaulieu, Raul R. Gainetdinov, Tatiana D. Sotnikova, Ranga R. Krishnan, David A. Schwartz, Redford B. Williams, Lauranell Burch
-
Publication number: 20100254907Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: April 1, 2010Publication date: October 7, 2010Inventors: Matthieu GUITTON, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Publication number: 20100255001Abstract: The present invention relates to a method of treating hepatitis comprising administering a serotonin blocker, and the use of such blockers in said treatment and in the manufacture of medicaments for treating hepatitis.Type: ApplicationFiled: September 22, 2008Publication date: October 7, 2010Inventors: Karl Lang, Philipp Lang, Hans Hengartner, Rolf Zinkernagel, Panco Georgiev
-
Publication number: 20100247543Abstract: The treatment and prevention of neurodegenerative diseases by repression of the transcriptional complex that silences the promoter of the UCHL1 gene.Type: ApplicationFiled: February 24, 2010Publication date: September 30, 2010Applicant: ORYZON GENOMICS, S.A.Inventors: Tamara Maes, Marta Barrachina Castillo, Isidro Ferrer Abizanda
-
Publication number: 20100234349Abstract: This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.Type: ApplicationFiled: September 4, 2007Publication date: September 16, 2010Inventors: Gunnar M. Olsen, Dan Peters, Bjarne H. Dahl, Jeppe Kejser Christensen, Steven Charles Loechel, Daniel B. Timmermann
-
Patent number: 7790772Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.Type: GrantFiled: August 10, 2009Date of Patent: September 7, 2010Assignee: Sepracor Inc.Inventors: Thomas Jerussi, Qun Kevin Fang, Mark G. Currie
-
Publication number: 20100221321Abstract: A method and apparatus for delivering a plurality of medicaments in a single delivery vehicle for the management of co-morbid diseases, illnesses and conditions. The present invention provides a novel delivery process for many medicaments. Medicaments may be encapsulated and stored separately within a larger capsule until the time of ingestion, consumption, or the like. Benefits of the present invention include maintaining separation of distinct ingredients within a single capsule and the capability to control the time release of multiple ingredients within the capsule.Type: ApplicationFiled: March 9, 2010Publication date: September 2, 2010Applicant: INNERCAP Technologies, Inc.Inventors: Frederick H. MILLER, James H. Ruble, Gary D.E. Pierce
-
Publication number: 20100210654Abstract: The present invention relates to novel P2Y12 receptor antagonists useful for treating, alleviating and/or preventing diseases and disorders related to P2Y12 receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The present invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviation, prevention and/or treatment of diseases and disorders, especially the use as antithrombotic agents for inhibiting platelet aggregation.Type: ApplicationFiled: March 7, 2008Publication date: August 19, 2010Applicant: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONNInventors: Christa E. Müller, Younis Baqi
-
Publication number: 20100196466Abstract: A novel encapsulated product is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided.Type: ApplicationFiled: January 29, 2010Publication date: August 5, 2010Applicant: Capricorn Pharma Inc.Inventor: S. Rao CHERUKURI
-
Publication number: 20100190764Abstract: This invention relates to novel Spiro cyclopentane derivatives of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders.Type: ApplicationFiled: July 24, 2008Publication date: July 29, 2010Inventors: Emiliano Castiglioni, Romano Di Fabio, Massimo Gianotti, Milan Mesic, Francesca Pavone, Slavko Rast, Luigi Piero Stasi
-
Patent number: 7759397Abstract: The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry I or 2 radicals Rb; X is N or CH; E is CR6R7 or NR3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H or R1a and R2 or R1a and R2a together are (CH2)n with n being 1, 2, 3 or 4; R2 and R2a each independently are H, CH3, CH2F, CHF2 or CF3; R3 is H or C,-C4-alkyl; and the physiologically tolerated acid addition salts of these compounds.Type: GrantFiled: October 14, 2005Date of Patent: July 20, 2010Assignee: Abbott GmbH & Co. KGInventors: Karla Drescher, Andreas Haupt, Liliane Unger, Sean C. Turner, Wilfried Braje, Roland Grandel
-
Patent number: 7754703Abstract: The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P1 receptor type. The compounds invention include compounds having a phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates, and phosphothionates.Type: GrantFiled: February 14, 2006Date of Patent: July 13, 2010Assignee: University of Virginia Patent FoundationInventors: Kevin R. Lynch, Timothy L. Macdonald
-
Patent number: 7750051Abstract: The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof.Type: GrantFiled: December 13, 2007Date of Patent: July 6, 2010Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Anton Frenkel, Tamas Koltai
-
Publication number: 20100168239Abstract: Disclosed is a method for the treatment of Multiple System Atrophy comprising administering to a subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 21, 2007Publication date: July 1, 2010Inventor: Werner Poewe
-
Publication number: 20100158956Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.Type: ApplicationFiled: December 22, 2009Publication date: June 24, 2010Inventor: James R. Komorowski
-
Publication number: 20100105637Abstract: The invention involves sustained-release pharmaceutical compositions containing a water-soluble ionic small molecule pharmaceutical agent complexed with an oppositely charged surfactant, particularly a natural bile surfactant. The complexes are sustained-release ionic complexes. The complexes release the ionic pharmaceutical agents into aqueous solution slowly and with zero-order kinetics. Thus, they can be formulated into sustained-release pharmaceutical compositions.Type: ApplicationFiled: October 22, 2009Publication date: April 29, 2010Inventor: Cherng-ju Kim
-
Patent number: 7700122Abstract: A topical opioid paradigm was developed to determine analgesic peripheral effects of morphine. Topical morphine as well as peptides such as [D-Ala2,MePhe4,Gly(ol)5]enkephalin (DAMGO) produced a potent, dose-dependent analgesia using the radiant heat tailflick assay. The topical drugs potentiated systemic agents, similar to the previously established synergy between peripheral and central sites of action. Local tolerance was rapidly produced by repeated daily topical exposure to morphine. Topical morphine tolerance was effectively blocked by the N-Methyl-D-Aspartate (NMDA) receptors antagonist MK801 and ketamine given either systemically or topically. NMDA receptor antagonists reversed pre-existing morphine tolerance. The activity of topical NMDA antagonists to block local morphine tolerance suggests that peripheral NMDA receptors mediate topical morphine tolerance.Type: GrantFiled: July 15, 1999Date of Patent: April 20, 2010Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Yuri Kolesnikov, Gavril W. Pasternak
-
Publication number: 20100092479Abstract: The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E).Type: ApplicationFiled: August 17, 2009Publication date: April 15, 2010Applicant: CombinatoRx (Singapore) Pte. Ltd.Inventors: Lisa M. Johansen, Christopher M. Owens
-
Publication number: 20100093805Abstract: The present invention relates to a method of treating or alleviating the symptoms of amblyopia. It is based on the discovery that repeated administration of a specific drug, which is known to be clinically active to treat depression in humans, results in improved vision of the amblyopic eye.Type: ApplicationFiled: June 27, 2008Publication date: April 15, 2010Applicant: HERMO PHARMA OYInventors: Eero Castrén, Lamberto Maffei, Jose Maya Vetencourt
-
Publication number: 20100081713Abstract: The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).Type: ApplicationFiled: March 18, 2009Publication date: April 1, 2010Inventors: Geeta Sharma, Ralf Altmeyer, Vishal Pendharker, Yu Chen, Michael Foley
-
Publication number: 20100041747Abstract: The present invention relates to the use of certain spiro, ketone and carboxylic acid compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins and the use of these compounds for the production of a cosmetic or pharmaceutical composition for the promotion of hair growth or for the treatment or prevention of inflammatory autoimmune diseases, of diseases caused by fungi, of bacterial infections, of viral infections, of diseases caused by parasites, protozoa or worms, of cancer, of diseases of cells, of fibrosing diseases, and of non-neoplastic changes and diseases which are attributable to prions and changes in the structure and function of cellular proteins and cells.Type: ApplicationFiled: August 14, 2007Publication date: February 18, 2010Applicants: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Heinrich-Heine-Universitat DusseldorfInventors: Gunter Fischer, Cordelia Schiene-Fischer, Sebastian Daum, Gerhard Küllertz, Manfred Braun
-
Patent number: 7662805Abstract: Oral antidepressant formulation comprising an effective antidepressant amount of at least one pharmaceutically acceptable antidepressant active agent and an effective amount lower than 50 mg of acetylsalicylic acid, derivatives of acetylsalicylic acid, or diaspirin, for reducing the onset of antidepressant action.Type: GrantFiled: December 6, 2004Date of Patent: February 16, 2010Inventors: Julien Mendlewicz, Philippe Kriwin, Roland Powis De Tenbossche
-
Publication number: 20100022570Abstract: Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides. Formula (I), wherein X is oxygen or sulfur; A is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, or a phenyl ring; the heterocyclic ring or the phenyl being substituted by the groups R6, R7 and R8; R6, R7 and R8 are each, independently, hydrogen, halogen, cyano, nitro, C1-4 alky, C1-4 halogenalkyl, C1-4 halogenalkoxy, C1-4 alkoxy(C1-4)alkyl or C1-4halo-genalkoxy(C1-4)alkyl, provided that at least one of R6, R7 and R8 is not hydrogen; B is a phenyl, naphthyl or quinolinyl group, which is substituted by one or more substituents R9.Type: ApplicationFiled: May 16, 2007Publication date: January 28, 2010Applicants: SYNGENTA CROP PROTECTION, INC., SYNGENTA LIMITEDInventors: Daniel Stierli, John J. Taylor, Harald Walter, Paul Anthony Worthington
-
Publication number: 20100016280Abstract: Activation of 5-HT2A receptors using agonists at surprisingly low concentrations was shown to potently inhibit TNF-?-induced inflammation in multiple cell types. Significantly, proinflammatory markers were also inhibited by the agonist, (R)-DOI, even many hours after treatment with TNF-?. With the exception of a few natural toxins, no current drugs or small molecule therapeutics demonstrate a comparable potency for any physiological effect. TNF-? and TNF-? receptor mediated inflammatory pathways have been strongly implicated in a number of diseases, including atherosclerosis, asthma, rheumatoid arthritis, psoriasis, type II diabetes, depression, schizophrenia, and Alzheimer's disease. Importantly, because (R)-DOI can significantly inhibit the effects of TNF-? many hours after the administration of TNF-?, potential therapies could be aimed not only at preventing inflammation, but also treating inflammatory injury that has already occurred or is ongoing.Type: ApplicationFiled: July 10, 2009Publication date: January 21, 2010Inventors: Charles D. Nichols, Bangning Yu
-
Publication number: 20100010095Abstract: Disclosed is crystalline R(+)-N-propargyl-1-aminoindan and racemic N-propargyl-1-aminoindan characterized by colorless crystals a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is pure liquid R(+)-N-propargyl-1-aminoindan and a pharmaceutical composition comprising the same, and the process for the manufacture thereof.Type: ApplicationFiled: June 19, 2009Publication date: January 14, 2010Inventor: Anton Frenkel
-
Publication number: 20100009970Abstract: The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.Type: ApplicationFiled: March 18, 2009Publication date: January 14, 2010Applicant: Combinatorx (Singapore) Pte. Ltd.Inventors: Lisa M. Johansen, Christopher M. Owens, Christina Mawhinney, Todd W. Chappell, Alexander T. Brown, Michael G. Frank, Michael A. Foley, Ralf Altmeyer, Yu Chen
-
Publication number: 20100004311Abstract: Sensitive human skin/scalp/mucous membrane conditions, for example skin irritation and/or dry patches and/or erythemas and/or dysaesthesic sensations and/or sensations of heating and/or pruritus, are therapeutically treated by topically applying thereto an effective condition-alleviating amount of at least one inhibitor of at least one excitatory amino acid.Type: ApplicationFiled: September 10, 2009Publication date: January 7, 2010Applicant: L'OREALInventors: Lionel Breton, Isabelle Nonotte
-
Patent number: 7638651Abstract: Disclosed herein are substituted cyclohexanone-based NMDA receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: April 25, 2008Date of Patent: December 29, 2009Assignee: Auspex PharmaceuticalsInventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20090297619Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.Type: ApplicationFiled: June 11, 2009Publication date: December 3, 2009Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
-
Patent number: 7612114Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R? represents 1 to 4 independent hydrogen atoms and the like; and R? represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.Type: GrantFiled: June 22, 2005Date of Patent: November 3, 2009Assignee: Eisai R&D Management Co., Ltd.Inventors: Shinichi Hamaoka, Noritaka Kitazawa, Kazumasa Nara, Atsushi Sasaki, Atsushi Kamada, Tadashi Okabe
-
Publication number: 20090270367Abstract: The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.Type: ApplicationFiled: March 3, 2009Publication date: October 29, 2009Inventors: Varghese JOHN, Michel MAILLARD, John TUCKER, Jose AQUINO, Barbara JAGODZINSKA, Louis BROGLEY, Jay TUNG, Simeon BOWERS, Darren DRESSEN, Gary PROBST, Neerav SHAH
-
Patent number: 7589237Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.Type: GrantFiled: July 15, 2008Date of Patent: September 15, 2009Assignee: Sepracor Inc.Inventors: Thomas Jerussi, Qun Kevin Fang, Mark G. Currie
-
Patent number: 7572834Abstract: The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.Type: GrantFiled: December 5, 2006Date of Patent: August 11, 2009Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Jeffrey Sterling, David Lerner, Harel Rosen, Leonid Bronov, Dalia Medini-Green, Berta Iosefzon, Tirtsah Berger-Peskin, Ramy Lidor-Hadas, Eliezer Bahar
-
Publication number: 20090198145Abstract: Compositions, kits, methods, and systems to induce, maintain, monitor, and interpret a continuous, un-fragmented REM sleep state in humans, generate dreams, recover sleep, create brain neuronal plasticity and activate the brain for cognition enhancement and mood stabilization are described. If potentially combined with other medications, a platform is provided to develop new research and therapies in many fields treating the human brain. The procedure reliably and quickly generates a Continuous REM Sleep cycle of pre-determined time or indefinite duration depending on therapeutic goals, allowing the patient to experience a qualitatively superior dream sleep in a shortened period of time compared to a natural sleep cycle. Profuse positive (pleasant) dreams are produced as well. REM sleep, dreams and sleep recovery can be reliably generated, and various sleep, psychological and neurological illnesses and disorders can be treated or prevented either solely by this method or in combination with additional agents.Type: ApplicationFiled: December 8, 2008Publication date: August 6, 2009Inventor: Harrison CHOW
-
Publication number: 20090192166Abstract: A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enhancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.Type: ApplicationFiled: March 4, 2009Publication date: July 30, 2009Applicant: Duke UniversityInventors: Ranga R. Krishnan, Marc G. Caron, Xiaodong Zhang, Martin Beaulieu, Raul R. Gainetdinova, Tatiana D. Sotnikova